Head to Head Review: GeneNews (OTCMKTS:GNWSF) and Lantheus (OTCMKTS:LNTH)

Lantheus (NASDAQ:LNTH) and GeneNews (OTCMKTS:GNWSF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Valuation & Earnings

This table compares Lantheus and GeneNews’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lantheus $343.37 million 3.25 $40.51 million $0.94 30.55
GeneNews $410,000.00 57.07 -$2.94 million N/A N/A

Lantheus has higher revenue and earnings than GeneNews.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lantheus and GeneNews, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus 0 1 1 0 2.50
GeneNews 0 0 0 0 N/A

Lantheus currently has a consensus price target of $20.50, suggesting a potential downside of 28.62%. Given Lantheus’ higher possible upside, research analysts clearly believe Lantheus is more favorable than GeneNews.

Risk & Volatility

Lantheus has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, GeneNews has a beta of 5.3, suggesting that its share price is 430% more volatile than the S&P 500.


This table compares Lantheus and GeneNews’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lantheus 12.17% 59.57% 8.85%
GeneNews N/A N/A N/A

Institutional and Insider Ownership

92.6% of Lantheus shares are owned by institutional investors. 2.6% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


Lantheus beats GeneNews on 9 of the 11 factors compared between the two stocks.

Lantheus Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures to assess blood flow to the muscle of the heart; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical used in the manufacture of sources for the calibration and maintenance of single-photon emission computed tomography imaging cameras. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment follow-up of neuroendocrine tumors. The company sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.

GeneNews Company Profile

GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.